Inhaled pulmonary vasodilator therapy for management of right-ventricular dysfunction after left ventricular assist device placement and cardiac transplantation.
Pharmacotherapy 2017 May 24. Epub 2017 May 24.
Clinical Pharmacy Manager, Heart Transplant and Mechanical Circulatory Support; NewYork-Presbyterian Hospital, Columbia University Medical Center, Department of Pharmacy, New York, NY.
Right ventricular failure (RVF) after cardiac transplant (CTX) or implantation of a continuous-flow left ventricular assist device (CF-LVAD) is associated with significant post-operative morbidity and mortality. A variety of modalities have been used to treat post-operative RVF, including management of volume status, intravenous inotropes and vasodilators, and right-sided mechanical support. Inhaled vasodilator agents are a unique treatment option aimed at minimizing systemic absorption by delivering therapy directly to the pulmonary vasculature. Read More